Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 28, 2025
Business Overview: Henry Schein is a global provider of health care products and services to office-based dental and medical practitioners. The company operates through three reportable segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 28, 2025 |
Six Months Ended June 28, 2025 |
Six Months Ended June 29, 2024 |
|---|---|---|---|
| Net Sales | $3,240 | $6,408 | $6,308 |
| Gross Profit | $1,016 | $2,016 | $2,030 |
| Gross Margin % | 31.4% | 31.5% | 32.2% |
| Operating Income | $151 | $326 | $309 |
| Net Income (Total) | $94 | $207 | $203 |
| Net Income Attributable to HSIC | $86 | $196 | $197 |
| Diluted EPS (HSIC) | $0.70 | $1.58 | $1.52 |
| Operating Cash Flow (6mo) | N/A | $157 | $493 |
| Total Debt | N/A | $3,018 | $2,536 |
| Cash and Equivalents | $145 | $145 | $138 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3.3% year-over-year for the quarter and 1.6% for the six-month period. Growth was driven by acquisitions (0.8% impact) and foreign exchange (0.6% impact), partially offset by lower pricing in U.S. dental merchandise and market uncertainty regarding tariffs affecting dental equipment sales.
- Profitability: Operating income decreased slightly for the quarter ($151M vs. $159M) but increased for the six-month period ($326M vs. $309M). Gross margin declined slightly due to lower glove pricing and product mix shifts.
- Restructuring Costs: The company recorded $23 million in restructuring charges for the quarter and $48 million for the six months under the "2024 Plan," compared to $15 million and $25 million, respectively, in the prior year periods. These costs relate to severance, accelerated amortization, and exit costs.
- Cash Flow: Operating cash flow for the six months ended June 28, 2025, was $157 million, a significant decrease from $493 million in the prior year. This variance is primarily attributed to changes in working capital accounts (receivables, inventory, payables) and the normalization of cash collections following the 2023 cyber incident.
- Debt Levels: Total debt increased to $3.018 billion from $2.536 billion at the end of 2024, driven by increased borrowings on bank credit lines and the U.S. trade accounts receivable securitization facility.
Guidance, Outlook, and Risks
- Restructuring Outlook: The company expects to continue recording restructuring charges associated with the 2024 Plan through the end of 2025, though a total estimate has not been determined.
- Tax Legislation: On July 4, 2025, the "One Big Beautiful Bill Act" (OBBBA) was signed into law. This legislation includes significant changes to corporate tax rates, Medicaid enrollment reductions, and international tax provisions. Management is currently assessing the impact on financial statements.
- Tariffs and Trade: New and increased U.S. tariffs on imports have created a volatile environment. While not materially impacting results in the first half of 2025, market uncertainty related to tariffs temporarily impacted U.S. dental equipment sales in the second quarter.
- Cyber Incident: The company incurred no direct expenses related to the October 2023 cyber incident in the current period. Insurance recoveries totaling $30 million were received in the first half of 2025, concluding the recovery process.
- Capital Allocation: The company executed a $250 million accelerated share repurchase program in May 2025. Additionally, KKR invested $250 million for approximately 12.5% of the company's common stock in May 2025.
Investor Verification Checklist
- Working Capital Trends: Verify the sustainability of the decline in operating cash flow ($157M vs. $493M prior year) and monitor accounts receivable days sales outstanding (44.7 days) and inventory turns (4.7) for signs of normalization or further strain.
- Restructuring Execution: Track the remaining estimated costs of the 2024 restructuring plan and the timeline for realizing associated efficiency gains.
- Tax Impact Assessment: Monitor management's update on the financial impact of the OBBBA tax legislation signed in July 2025, particularly regarding corporate tax rates and Medicaid funding.
- Tariff Exposure: Assess the long-term impact of evolving U.S. tariff policies on the cost of goods sold and pricing power in the dental equipment and merchandise segments.
- Debt Servicing: Review the increased debt load ($3.018B) and interest expense ($73M for six months) in the context of current interest rates and the company's leverage ratios.